Omeros Corporation Announces Royalty Monetization Transaction with DRI Healthcare TrustBusiness Wire • 10/03/22
Omeros Corporation Reports Narsoplimab Treatment Results in Critically Ill COVID-19 Patients in I-SPY COVID TrialBusiness Wire • 09/15/22
I-SPY COVID Trial Sponsored by Quantum Leap Healthcare Collaborative Reports Assessment of Narsoplimab for Treatment of Critically Ill Patients With COVID-19Business Wire • 09/15/22
Omeros Corporation Receives Interim Response from FDA on Formal Dispute Resolution Request for NarsoplimabBusiness Wire • 08/17/22
Omeros Corporation (OMER) CEO Gregory Demopulos on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/10/22
Wall Street Analysts See a 126% Upside in Omeros (OMER): Can the Stock Really Move This High?Zacks Investment Research • 08/04/22
Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022Business Wire • 08/04/22
FDA Grants Orphan Drug Designation to Omeros' MASP-3 Inhibitor OMS906 for Treatment of Paroxysmal Nocturnal HemoglobinuriaBusiness Wire • 07/29/22
Omeros Corporation (OMER) CEO Greg Demopulos on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/11/22
Omeros Corporation to Announce First Quarter Financial Results on May 10, 2022Business Wire • 05/04/22
Omeros Announces Journal of Clinical Oncology Publication Detailing Pivotal Trial Results for Narsoplimab in HSCT-TMABusiness Wire • 04/20/22
Omeros Corporation's (OMER) CEO Greg Demopulos on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/02/22
Omeros Corporation Reports Fourth Quarter and Year-End 2021 Financial ResultsBusiness Wire • 03/01/22
Omeros Corporation to Announce Fourth Quarter and Year-end Financial Results on March 1, 2022Business Wire • 02/24/22